Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study Meeting Abstract
| Authors: | Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T.; Coombs, C. C.; Flinn, I. W.; Lewis, D. J.; Le Gouill, S.; Palomba, M. L.; Woyach, J. A.; Pagel, J. M.; Lamanna, N.; Barve, M. A.; Ghia, P.; Eyre, T. A.; Zinzani, P. L.; Ujjani, C. S.; Koh, Y.; Izutsu, K.; Lech-Maranda, E.; Tam, C. S.; Sundaram, S.; Yin, M.; Nair, B.; Tsai, D. E.; Balbas, M.; Mato, A. R.; Cheah, C. Y.; Wang, M. L. |
| Abstract Title: | Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study |
| Meeting Title: | 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | clinical trial; lymphoma; phase; i/ii; mantle cell; mcl; pirtobrutinib; btki |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Sep 28-Oct 1 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S394 |
| End Page: | S395 |
| Language: | English |
| ACCESSION: | WOS:000897948100448 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(22)01569-5 |
| Notes: | Meeting Abstract: MCL-133 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
